Review



human kras mutant crc cell lines  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC human kras mutant crc cell lines
    Human Kras Mutant Crc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 8410 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kras mutant crc cell lines/product/ATCC
    Average 99 stars, based on 8410 article reviews
    human kras mutant crc cell lines - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    human kras mutant crc cell lines  (ATCC)
    99
    ATCC human kras mutant crc cell lines
    Human Kras Mutant Crc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kras mutant crc cell lines/product/ATCC
    Average 99 stars, based on 1 article reviews
    human kras mutant crc cell lines - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    human crc cell lines with mutant  (ATCC)
    96
    ATCC human crc cell lines with mutant
    Effect of ATRi on radiosensitivity. <t>(A)</t> <t>ARID1A</t> expression in colon cancer lines; (B) Effect of ATRi (VE822) on radiosensitivity. ARID1A+ and ARID1A- cell lines were pre-treated for 1 h with 20 nM VE822 and irradiated with 0 Gy, 2 Gy, 4 Gy and 6 Gy. Plating efficiency of sham treated (untr) and VE822 treated (ATRi) cells were plotted as log10 for ARID1A + and ARID1A - cell lines. Results of 3 independent experiments are shown for <t>CRC</t> cell lines.
    Human Crc Cell Lines With Mutant, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human crc cell lines with mutant/product/ATCC
    Average 96 stars, based on 1 article reviews
    human crc cell lines with mutant - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    isogenic human dld-1 crc cell lines expressing either wild-type or mutant k-ras  (Johns Hopkins HealthCare)
    90
    Johns Hopkins HealthCare isogenic human dld-1 crc cell lines expressing either wild-type or mutant k-ras
    Effect of ATRi on radiosensitivity. <t>(A)</t> <t>ARID1A</t> expression in colon cancer lines; (B) Effect of ATRi (VE822) on radiosensitivity. ARID1A+ and ARID1A- cell lines were pre-treated for 1 h with 20 nM VE822 and irradiated with 0 Gy, 2 Gy, 4 Gy and 6 Gy. Plating efficiency of sham treated (untr) and VE822 treated (ATRi) cells were plotted as log10 for ARID1A + and ARID1A - cell lines. Results of 3 independent experiments are shown for <t>CRC</t> cell lines.
    Isogenic Human Dld 1 Crc Cell Lines Expressing Either Wild Type Or Mutant K Ras, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/isogenic human dld-1 crc cell lines expressing either wild-type or mutant k-ras/product/Johns Hopkins HealthCare
    Average 90 stars, based on 1 article reviews
    isogenic human dld-1 crc cell lines expressing either wild-type or mutant k-ras - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    human kras mutant crc cell line hct116  (ATCC)
    99
    ATCC human kras mutant crc cell line hct116
    Effect of ATRi on radiosensitivity. <t>(A)</t> <t>ARID1A</t> expression in colon cancer lines; (B) Effect of ATRi (VE822) on radiosensitivity. ARID1A+ and ARID1A- cell lines were pre-treated for 1 h with 20 nM VE822 and irradiated with 0 Gy, 2 Gy, 4 Gy and 6 Gy. Plating efficiency of sham treated (untr) and VE822 treated (ATRi) cells were plotted as log10 for ARID1A + and ARID1A - cell lines. Results of 3 independent experiments are shown for <t>CRC</t> cell lines.
    Human Kras Mutant Crc Cell Line Hct116, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human kras mutant crc cell line hct116/product/ATCC
    Average 99 stars, based on 1 article reviews
    human kras mutant crc cell line hct116 - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Effect of ATRi on radiosensitivity. (A) ARID1A expression in colon cancer lines; (B) Effect of ATRi (VE822) on radiosensitivity. ARID1A+ and ARID1A- cell lines were pre-treated for 1 h with 20 nM VE822 and irradiated with 0 Gy, 2 Gy, 4 Gy and 6 Gy. Plating efficiency of sham treated (untr) and VE822 treated (ATRi) cells were plotted as log10 for ARID1A + and ARID1A - cell lines. Results of 3 independent experiments are shown for CRC cell lines.

    Journal: Frontiers in Oncology

    Article Title: Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy

    doi: 10.3389/fonc.2022.999626

    Figure Lengend Snippet: Effect of ATRi on radiosensitivity. (A) ARID1A expression in colon cancer lines; (B) Effect of ATRi (VE822) on radiosensitivity. ARID1A+ and ARID1A- cell lines were pre-treated for 1 h with 20 nM VE822 and irradiated with 0 Gy, 2 Gy, 4 Gy and 6 Gy. Plating efficiency of sham treated (untr) and VE822 treated (ATRi) cells were plotted as log10 for ARID1A + and ARID1A - cell lines. Results of 3 independent experiments are shown for CRC cell lines.

    Article Snippet: The human CRC cell lines with mutant (LS180, RKO, SW48) and wild-type (HCT15, HCT116 and Colo320DM) ARID1A were obtained from ATCC (LGC Standards, Wesel, Germany) and were designated as ARID1A - and ARID1A + cells, respectively.

    Techniques: Expressing, Irradiation

    Cell cycle effect of ATRi/ARID1A. (A) Synchronized cells in early S phase and mid S phase were pre-treated for 1 h with VE822 and irradiated thereafter with 0 Gy, 2 Gy and 4 Gy. Plating efficiency of sham treated (untr) and VE822 treated (ATRi) cells were plotted as log10 for ARID1A + and ARID1A - cell lines. (B) Exit from G2 phase into the M phase was measured after treatment with VE822 and irradiation in ARID1A - SW48 and ARID1A + HCT116 cell lines. Fraction of phospho-histone H3 positive cells were plotted against time after irradiation. MI = phospho-histone H3 in radiation/phospho-histone H3 in no-radiation × 100%. Results of 3 independent experiments are shown for CRC cell lines.

    Journal: Frontiers in Oncology

    Article Title: Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy

    doi: 10.3389/fonc.2022.999626

    Figure Lengend Snippet: Cell cycle effect of ATRi/ARID1A. (A) Synchronized cells in early S phase and mid S phase were pre-treated for 1 h with VE822 and irradiated thereafter with 0 Gy, 2 Gy and 4 Gy. Plating efficiency of sham treated (untr) and VE822 treated (ATRi) cells were plotted as log10 for ARID1A + and ARID1A - cell lines. (B) Exit from G2 phase into the M phase was measured after treatment with VE822 and irradiation in ARID1A - SW48 and ARID1A + HCT116 cell lines. Fraction of phospho-histone H3 positive cells were plotted against time after irradiation. MI = phospho-histone H3 in radiation/phospho-histone H3 in no-radiation × 100%. Results of 3 independent experiments are shown for CRC cell lines.

    Article Snippet: The human CRC cell lines with mutant (LS180, RKO, SW48) and wild-type (HCT15, HCT116 and Colo320DM) ARID1A were obtained from ATCC (LGC Standards, Wesel, Germany) and were designated as ARID1A - and ARID1A + cells, respectively.

    Techniques: Irradiation

    Effect of ATRi on ɣH2AX foci formation in G2-phase CRC cell lines.Maximum intensity projection (MIP) images of γH2AX foci (red) at tmax (1h) in G2-phase ARID1A + (A, B) and ARID1A - (C, D) cells without (untr) and with 20 nM VE822 (ATRi) in EdU - (green) cells after exposure to the indicated IR doses. Cells were counterstained with DAPI (blue). The respective numbers of γH2AX foci at tmax as a function of IR dose are shown in (B) (ARID1A + cells) and (D) (ARID1A - cells). Results of 3 independent experiments are shown for CRC cell lines.

    Journal: Frontiers in Oncology

    Article Title: Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy

    doi: 10.3389/fonc.2022.999626

    Figure Lengend Snippet: Effect of ATRi on ɣH2AX foci formation in G2-phase CRC cell lines.Maximum intensity projection (MIP) images of γH2AX foci (red) at tmax (1h) in G2-phase ARID1A + (A, B) and ARID1A - (C, D) cells without (untr) and with 20 nM VE822 (ATRi) in EdU - (green) cells after exposure to the indicated IR doses. Cells were counterstained with DAPI (blue). The respective numbers of γH2AX foci at tmax as a function of IR dose are shown in (B) (ARID1A + cells) and (D) (ARID1A - cells). Results of 3 independent experiments are shown for CRC cell lines.

    Article Snippet: The human CRC cell lines with mutant (LS180, RKO, SW48) and wild-type (HCT15, HCT116 and Colo320DM) ARID1A were obtained from ATCC (LGC Standards, Wesel, Germany) and were designated as ARID1A - and ARID1A + cells, respectively.

    Techniques:

    Effect of ATRi on RAD51 foci formation in G2-phase CRC cells. Maximum intensity projection (MIP) images of RAD51 foci (red) at tmax (6h) in G2-phase ARID1A+ (A, B) and ARID1A- (C, D) cells without (untr) and with 20 nM VE822 (ATRi) in EdU- (green) cells after exposure to the indicated IR doses. Cells were counterstained with DAPI (blue). The respective numbers of Rad51 foci at tmax as a function of IR dose are shown in (B) (ARID1A+ cells) and (D) (ARID1A- cells). Results of 3 independent experiments are shown for CRC cell lines.

    Journal: Frontiers in Oncology

    Article Title: Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy

    doi: 10.3389/fonc.2022.999626

    Figure Lengend Snippet: Effect of ATRi on RAD51 foci formation in G2-phase CRC cells. Maximum intensity projection (MIP) images of RAD51 foci (red) at tmax (6h) in G2-phase ARID1A+ (A, B) and ARID1A- (C, D) cells without (untr) and with 20 nM VE822 (ATRi) in EdU- (green) cells after exposure to the indicated IR doses. Cells were counterstained with DAPI (blue). The respective numbers of Rad51 foci at tmax as a function of IR dose are shown in (B) (ARID1A+ cells) and (D) (ARID1A- cells). Results of 3 independent experiments are shown for CRC cell lines.

    Article Snippet: The human CRC cell lines with mutant (LS180, RKO, SW48) and wild-type (HCT15, HCT116 and Colo320DM) ARID1A were obtained from ATCC (LGC Standards, Wesel, Germany) and were designated as ARID1A - and ARID1A + cells, respectively.

    Techniques:

    Effect of ATRi on HR repair in reporter cell lines. (A) Western blot results of ARID1A knock-down in DR-GFP-U2OS and DR-GFP-A549 reporter cells; GAPDH was used as an internal control. (B) Normalized GFP expression in DR-GFP- U2OS and DR-GFP-A549 reporter cells after treatment with control siRNA (mock), 20 nM VE822 (ATRi), ARID1A specific siRNA (siARID1A) and ATRi after knock-down of ARID1A (siARID1A, ATRi). (C) Normalized GFP expression in SA-GFP- U2OS reporter cells after treatment with control siRNA (mock), 20 nM VE822 (ATRi), ARID1A specific siRNA (siARID1A) and ATRi after knock-down of ARID1A (siARID1A, ATRi). (D) Normalized GFP expression in EJ2-GFP- U2OS reporter cells after treatment with control siRNA (mock), 20 nM VE822 (ATRi), ARID1A specific siRNA (siARID1A) and ATRi after knock-down of ARID1A (siARID1A, ATRi).Results of 3 independent experiments are shown for CRC cell lines.

    Journal: Frontiers in Oncology

    Article Title: Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy

    doi: 10.3389/fonc.2022.999626

    Figure Lengend Snippet: Effect of ATRi on HR repair in reporter cell lines. (A) Western blot results of ARID1A knock-down in DR-GFP-U2OS and DR-GFP-A549 reporter cells; GAPDH was used as an internal control. (B) Normalized GFP expression in DR-GFP- U2OS and DR-GFP-A549 reporter cells after treatment with control siRNA (mock), 20 nM VE822 (ATRi), ARID1A specific siRNA (siARID1A) and ATRi after knock-down of ARID1A (siARID1A, ATRi). (C) Normalized GFP expression in SA-GFP- U2OS reporter cells after treatment with control siRNA (mock), 20 nM VE822 (ATRi), ARID1A specific siRNA (siARID1A) and ATRi after knock-down of ARID1A (siARID1A, ATRi). (D) Normalized GFP expression in EJ2-GFP- U2OS reporter cells after treatment with control siRNA (mock), 20 nM VE822 (ATRi), ARID1A specific siRNA (siARID1A) and ATRi after knock-down of ARID1A (siARID1A, ATRi).Results of 3 independent experiments are shown for CRC cell lines.

    Article Snippet: The human CRC cell lines with mutant (LS180, RKO, SW48) and wild-type (HCT15, HCT116 and Colo320DM) ARID1A were obtained from ATCC (LGC Standards, Wesel, Germany) and were designated as ARID1A - and ARID1A + cells, respectively.

    Techniques: Western Blot, Knockdown, Control, Expressing

    Effect of ATRi on ex vivo explants from CRC patients. (A) Example of IHC staining of ARID1A expression from clinical CRC tumor cells with and without ARID1A expression. (B) Western blot of CK20 expression from primary CRC cells; GAPDH was used as an internal control. (C) ATP-Tumor Chemosensitivity Assay for the effect of the ATR inhibitor VE822 on ex-vivo cells from CRC patients. ATP activity was measured after treatment of ex-vivo cells with concentration ranged from 0, 2.5 up to 100 nM in cells from CRC patients with (+) and without (-) ARID1A expression.

    Journal: Frontiers in Oncology

    Article Title: Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy

    doi: 10.3389/fonc.2022.999626

    Figure Lengend Snippet: Effect of ATRi on ex vivo explants from CRC patients. (A) Example of IHC staining of ARID1A expression from clinical CRC tumor cells with and without ARID1A expression. (B) Western blot of CK20 expression from primary CRC cells; GAPDH was used as an internal control. (C) ATP-Tumor Chemosensitivity Assay for the effect of the ATR inhibitor VE822 on ex-vivo cells from CRC patients. ATP activity was measured after treatment of ex-vivo cells with concentration ranged from 0, 2.5 up to 100 nM in cells from CRC patients with (+) and without (-) ARID1A expression.

    Article Snippet: The human CRC cell lines with mutant (LS180, RKO, SW48) and wild-type (HCT15, HCT116 and Colo320DM) ARID1A were obtained from ATCC (LGC Standards, Wesel, Germany) and were designated as ARID1A - and ARID1A + cells, respectively.

    Techniques: Ex Vivo, Immunohistochemistry, Expressing, Western Blot, Control, Activity Assay, Concentration Assay